论文部分内容阅读
为探讨胰腺癌患者血浆中前列腺素Ｅ２（ｐｒｏｓｔａｇｌａｎｄｉｎＥ２，ＰＧＥ２）的含量及其意义，实验用放射免疫分析法测定１９例胰腺癌患者，６例胰腺良性疾病患者，５例良性黄疸患者，８例健康成人的外周静脉血浆中ＰＧＥ２水平。结果：胰腺癌患者ＰＧＥ２水平明显高于健康对照组，且术前术后相比呈显著性差异；良性胰腺疾病患者及良性黄疸患者血浆ＰＧＥ２水平与正常对照组相比均无显著差异。而与胰腺癌患者血浆ＰＧＥ２水平相比则具有显著差异。结论：胰腺癌与ＰＧＥ２关系密切，胰腺癌组织能产生ＰＧＥ２并释放入血；ＰＧＥ２水平测定对胰腺癌的诊断及鉴别诊断有应用价值。
To investigate the content and significance of prostaglandin E2 (PGE2) in plasma of patients with pancreatic cancer, 19 patients with pancreatic cancer, 6 patients with benign pancreatic disease, 5 patients with benign jaundice, and 8 healthy subjects were measured by radioimmunoassay. Peripheral venous plasma levels of PGE2 in adults. RESULTS: PGE2 levels in pancreatic cancer patients were significantly higher than those in healthy controls, and there were significant differences between preoperative and postoperative scores. There was no significant difference in plasma PGE2 levels between patients with benign pancreatic diseases and those with benign jaundice. However, there was a significant difference in plasma PGE2 levels from patients with pancreatic cancer. Conclusion: Pancreatic cancer is closely related to PGE2. Pancreatic cancer tissues can produce PGE2 and release into the blood. The determination of PGE2 level has application value in the diagnosis and differential diagnosis of pancreatic cancer.